18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

By R. Vandenberghe, K. Van Laere, A. Ivanoiu, Eric Salmon, C. Bastin, E. Triau, S. Hasselbalch, I. Law, Allan Andersen, A. Korner and 9 more. Annals of Neurology, 2010

666 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/bca568dca07d08655b5e915589714878d3ad4985

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “2011, 2012], F18-flutemetamol [Vandenberghe et al. 2010; Wolk et al. 2011], and F18-florbetaben [Rowe et al.”
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. (2016, background): “, 2004) or fluorinated amyloid PET tracers (Vandenberghe et al., 2010; Barthel et al., 2011; Clark et al., 2011) has had a”
β-Amyloid accumulation in the human brain after one night of sleep deprivation (2018, background): “ABB increases as a function of aging and AD severity, with an estimated 17% increase from younger to older adults (40).”
Brain imaging in Alzheimer disease. (2012, methodology): “…studies using each of the fluorine-18-labelled tracers, [F-18]florbetaben (18F-BAY94-9172 or AV-1; Rowe et al. 2008), [F-18]florbetapir (AV-45; Wong et al. 2010; Clark et al. 2011) and [F-18]flu- temetamol (3 0 F-PiB or GE-067; Nelissen et al. 2009; Vandenberghe et al. 2010) in AD patients.”
Prevalence of Amyloid PET Positivity in Dementia Syndromes (2015, unknown): “APOE ε4 noncarrier 160 5 (3-8) 14 (11-18)”